BIOMAT Database Logo BIOMAT Database Logo

[Complications of the treatment with long-acting neuroleptic preparations. Brain disease due to fluphenazine decanoate]. 1976

L Agostini, and S Biagini, and R Quartesan

UI MeSH Term Description Entries
D001927 Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. Intracranial Central Nervous System Disorders,Brain Disorders,CNS Disorders, Intracranial,Central Nervous System Disorders, Intracranial,Central Nervous System Intracranial Disorders,Encephalon Diseases,Encephalopathy,Intracranial CNS Disorders,Brain Disease,Brain Disorder,CNS Disorder, Intracranial,Encephalon Disease,Encephalopathies,Intracranial CNS Disorder
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005260 Female Females
D005476 Fluphenazine A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE. Flufenazin,Fluphenazine Hydrochloride,Lyogen,Prolixin,Hydrochloride, Fluphenazine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

L Agostini, and S Biagini, and R Quartesan
Long-acting phenothiazine (fluphenazine decanoate) treatment of psychosis.
April 1968, Archives of general psychiatry,
L Agostini, and S Biagini, and R Quartesan
A comparative study of two long acting phenothiazine preparations, fluphenazine-enanthate and fluphenazine-decanoate.
January 1966, Psychopharmacologia,
L Agostini, and S Biagini, and R Quartesan
Why a long-acting neuroleptic? Fluphenazine decanoate. (Brief review and clinical rationale).
January 1971, Psychosomatics,
L Agostini, and S Biagini, and R Quartesan
[Treatment of psychoses with a long-acting neuroleptic agent (fluphenazine decanoate). Clinico-psychopathological study of 53 patients].
January 1974, Acta neurologica,
L Agostini, and S Biagini, and R Quartesan
[Fluphenazine decanoate. A new long-acting phenothiazine].
January 1970, Nordisk psykiatrisk tidsskrift. Nordic journal of psychiatry,
L Agostini, and S Biagini, and R Quartesan
Outpatient treatment of psychotic patients with a long-acting phenothiazine: fluphenazine decanoate.
December 1971, The Medical journal of Malaya,
L Agostini, and S Biagini, and R Quartesan
[Use of fluphenazine decanoate in psychiatric therapy. Multicenter study in 1095 patients preselected for long-acting neuroleptic treatment].
January 1986, Minerva psichiatrica,
L Agostini, and S Biagini, and R Quartesan
Noroxyclothepin decanoate (VUFB-9976) long-acting neuroleptic drug.
May 1973, Activitas nervosa superior,
L Agostini, and S Biagini, and R Quartesan
An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
January 1989, Pharmatherapeutica,
L Agostini, and S Biagini, and R Quartesan
Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.
January 1982, Pharmacology,
Copied contents to your clipboard!